Nearly 200 infants in Europe have been fathered by sperm from a donor who unintentionally carried a serious genetic abnormality, raising concerns among authorities, medical professionals, and the impacted families. About 20% of the donor’s sperm had a mutation in the TP53 gene, a crucial tumor-suppressor that prevents cancer cells from proliferating. The donor was healthy and unaware of any health problems. Li-Fraumeni syndrome, a genetic disorder that puts carriers at up to 90% risk of acquiring cancer before the age of 60, with a particularly high likelihood of childhood cancer, is now present in children conceived with sperm carrying the mutation.
A few British women who traveled overseas for fertility treatment were among the recipients, according to the Human Fertilization and Embryology Authority (HFEA). After conducting a combined investigation with thirteen other public service broadcasters as part of the Investigative Journalism Network of the European Broadcasting Union, the BBC discovered the case. The study found that the donor’s sperm was utilized at 67 fertility clinics in 14 countries, resulting in at least 197 births; however, as not all cases have been traced, the true number may be higher.
Several of the children conceived using the donor’s sperm have already passed away, and some have already developed cancer. When Dr. Edwige Kasper presented preliminary results at the European Society of Human Genetics, which revealed that 23 out of 67 identified youngsters possessed the mutation and that 10 had already acquired cancer, concerns were immediately raised. “Many of our children have already been diagnosed with cancer,” she stated. Some of our children have already perished at a very young age, while others have already had two separate malignancies.
Li-Fraumeni syndrome is caused by a TP53 mutation that significantly raises the risk of different pediatric malignancies, osteosarcoma, brain tumors, breast cancer, and soft-tissue sarcomas. This gene failure puts youngsters at immediate and lifetime risk, in contrast to variants like BRCA that mostly harm adults. Regular ultrasounds and MRI scans are necessary for affected patients to check for tumors.
Receiving sperm that “wasn’t clean, that wasn’t safe, that carried a risk” was unacceptable, according to a single mother whose daughter had the mutation. The HFEA emphasized that no accredited UK clinics received any of the impacted sperm and pointed out that UK law restricts the use of donor sperm to ten families, a restriction that is not followed in many other nations.
This single donor is said to have conceived 53 children in Belgium, where the restriction is six families.
The Danish Patient Safety Authority has informed the UK that a few British women had got treatment at Danish clinics using the donor’s sperm, according to Peter Thompson, chief executive of the HFEA. The clinics involved told those ladies, he said. Because the mutation happened spontaneously in the donor prior to birth and was absent from his blood, genetic experts say it was unlikely to have been found during routine screening, rendering standard genetic tests useless. Professor Jackson Kirkman-Brown, a fertility specialist, stated that the lack of international restrictions on donor use is the true problem and that screening for such a mutation is very challenging because each sperm cell carries unique DNA variants. In an effort to stop repeat incidents, European reproductive health authorities are working to create cross-border family limitations.
As more families come forward, the number of children impacted might keep growing. The case has brought up important issues regarding international regulatory gaps, donor screening, and the obligations of cross-border fertility clinics.